A phase 1, randomized, double blind (3rd party open), placebo-controlled, parallel group, multicentre study to evaluate the multiple dose safety, tolerability, pharmacokinetics and pharmacodynamics, of PF-00868554 in hepatitis C virus (HCV) positive otherwise healthy patient volunteers

Trial Profile

A phase 1, randomized, double blind (3rd party open), placebo-controlled, parallel group, multicentre study to evaluate the multiple dose safety, tolerability, pharmacokinetics and pharmacodynamics, of PF-00868554 in hepatitis C virus (HCV) positive otherwise healthy patient volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2014

At a glance

  • Drugs Filibuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Apr 2011 Actual end date changed from May 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 31 Oct 2008 Results were presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 31 Oct 2008 Endpoint 'Viral load' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top